Pasireotide (SOM230) is Effective for the Treatment of Pancreatic Neuroendocrine Tumors (PNETs) in a Multiple Endocrine Neoplasia Type 1 (MEN1) Conditional Knockout Mouse Model

BACKGROUND: Pasireotide (SOM230), a long acting somatostatin analogue (LAR) has improved agonist activity at somatostatin receptors. We tested the effect of SOM230 on insulin secretion, glucose levels, tumor growth, and survival using an MEN1 transgenic mouse model. METHODS: Eight 12 month-old condi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Quinn, Thomas J., Yuan, Ziqiang, Adem, Asha, Geha, Rula, Vrikshajanani, Chakravarthy, Koba, Wade, Fine, Eugene, Hughes, David T., Schmid, Herbert, Libutti, Steven K.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3732168/
https://ncbi.nlm.nih.gov/pubmed/23102680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.surg.2012.08.021
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg